Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jane Wilcox

Advanced Heart Failure and Transplant Cardiology Chicago, IL Medical Doctor

NPI 1588820294 CMS profile 1149074

675 N Saint Clair St, Galter Pavillion Suite 18-200, General Medicine, Chicago, IL 60611

Open in the dashboard

General payments

$220,354

243 records reported · program years 2019–2025

Research payments

$6,050

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$63,236 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Jane Wilcox of Chicago, IL is reported in the CMS Open Payments database as having received $220,354 across 243 general payments and $6,050 in research payments paid to them. Separately, studies naming them as principal investigator received $63,236 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,805 23
2025 Research $5,850 2
2024 General $59,920 48
2023 General $58,891 47
2022 General $71,593 72
2021 General $9,312 21
2020 General $170 8
2019 General $4,664 24
2019 Research $200 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jane Wilcox
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Jane Wilcox were reported at $15,805. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Jane Wilcox Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $4,664 $863 $224–$4,562 $163
2020 $170 $452 $122–$3,992 $114
2021 $9,312 $550 $159–$3,571 $132
2022 $71,593 $729 $221–$4,357 $149
2023 $58,891 $1,002 $309–$5,827 $160
2024 $59,920 $931 $273–$5,204 $164
2025 $15,805 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $109,827 78 payments
  2. Abiomed $56,246 44 payments
  3. Abbott Laboratories $24,440 79 payments
  4. Lilly USA, LLC $20,700 12 payments
  5. Medtronic Vascular, Inc. $4,061 16 payments
  6. Amgen Inc. $2,380 1 payment
  7. Novartis Pharmaceuticals Corporation $2,010 3 payments
  8. Boston Scientific Corporation $150 1 payment
  9. Medtronic, Inc. $125 1 payment
  10. Edwards Lifesciences Corporation $120 1 payment
  11. Other $297 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $116,480 45 payments
  2. Honoraria $39,950 8 payments
  3. Travel and Lodging $29,167 57 payments
  4. Consulting Fee $20,130 10 payments
  5. Food and Beverage $8,543 114 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $6,084 9 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE Diabetes $92,167 58 payments
  2. Impella $45,533 30 payments
  3. JARDIANCE Diabetes $17,700 10 payments
  4. JARDIANCE Diabetes $17,660 20 payments
  5. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $10,129 26 payments
  6. CARDIOMEMS Heart failure $5,473 17 payments
  7. CARDIOMEMS Structural Heart $4,554 3 payments
  8. HeartMate 3 Left Ventricular Assist Device $2,326 10 payments
  9. ENTRESTO $2,010 3 payments
  10. HeartWare HVAD $952 8 payments
  11. Other $3,543 37 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Ionis Pharmaceuticals, Inc. $5,850 2 payments
  2. Medtronic Vascular, Inc. $200 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

2,396

Median for Cardiology: 2,533

Drug cost

$1,099,334

Median for Cardiology: $485,213

Branded share of claims

37.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 357 $460,978
Jardiance Empagliflozin Brand 203 $268,634
Eliquis Apixaban Brand 96 $140,901
Farxiga Dapagliflozin Propanediol Brand 70 $98,286
Prograf Tacrolimus Brand 24 $30,406
Tacrolimus Generic 115 $19,361
Xarelto Rivaroxaban Brand 12 $17,386
Repatha Sureclick Evolocumab Brand 17 $13,585
Veltassa Patiromer Calcium Sorbitex Brand 13 $11,949
Ozempic Semaglutide Brand 11 $10,673

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$57,361

Medicare's payments for the services billed

Medicare patients

227

Average age 71

Services billed

681

99 women, 128 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 71%
Chronic kidney disease 62%
Diabetes 53%
Atrial fibrillation 52%
Arthritis 44%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $17,660
  • Lilly USA, LLC $12,900
$30,560 203 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

246 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record